2nd prize in the Astrup prize competition:
The long-term benefits and harms associated with genetic inhibition of Cholesteryl Ester Transfer Protein

Cholesteryl Ester Transfer Protein (CETP) is an important protein in lipid metabolism. It facilitates the transport of cholesterol from high-density lipoproteins (HDLs) to triglyceride-rich lipoproteins and low-density lipoproteins (LDLs) in exchange for triglycerides. Pharmacological and genetic inhibition of CETP leads to a high level of cholesterol in HDL-particles and a low level of cholesterol in triglyceride-rich lipoproteins, LDLs, and lipoprotein(a) leading to a favorable lipid profile. The largest randomized clinical trial of a drug that inhibits CETP has shown an effect on reduction of risk of cardiovascular disease. Genetic studies have found that inhibition of CETP associated with a lower risk of cardiovascular disease but possibly also with a higher risk of age-related macular degeneration.

Det här är ett utplock av en intressant artikel från KBN – Nr. 1 – vol. 35 – 2023.